TIMP-1
Cross-source consensus on TIMP-1 from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Evidence quality
Highlighted claims
- The trial evaluates whether plasma TIMP-1 is associated with myocardial fibrosis and disease progression in chronic Chagas cardiomyopathy. — Prospective cohort study of TIMP-1 and myocardial fibrosis in Chagas disease at a reference clinic in Pernambuco, Brazil: PTICH trial protocol
- TIMP-1 regulates matrix metalloproteinases involved in extracellular matrix degradation. — Prospective cohort study of TIMP-1 and myocardial fibrosis in Chagas disease at a reference clinic in Pernambuco, Brazil: PTICH trial protocol
- TIMP-1 is being investigated as a non-invasive scalable biomarker that could complement CMR or serve as a pragmatic surrogate where CMR access is limited. — Prospective cohort study of TIMP-1 and myocardial fibrosis in Chagas disease at a reference clinic in Pernambuco, Brazil: PTICH trial protocol
- Overexpression of TIMP-1 is associated with increased collagen deposition and progression of myocardial fibrosis. — Prospective cohort study of TIMP-1 and myocardial fibrosis in Chagas disease at a reference clinic in Pernambuco, Brazil: PTICH trial protocol
- Prior evidence indicates that TIMP-1 levels are elevated in chronic Chagas heart disease. — Prospective cohort study of TIMP-1 and myocardial fibrosis in Chagas disease at a reference clinic in Pernambuco, Brazil: PTICH trial protocol